Krystal Biotech IncKRYS
Price$325.31Intrinsic value$377.6316% above price

Valuation

How Intrinsic Value compares with model outputs

Intrinsic Value $377.63median of 6 methods · middle span $208-$1,886based on filings through 30 Jun 2026
Market Price $325.31Price as of 1 Oct 2026
Margin of Safety +16.1%as of 1 Oct 2026

Valuation methods vs. Market Price

Company vs. peer median Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions

ParameterValue
Years 1–5: analyst growth pathFive-year total matches analyst consensus exactly. Year 1: 9.1% (near-term consensus, capped) · years 2–5: 35.7%/yr (balance of the path).29.9% per year
Years 6–10: glide to demonstrated growth
Per-year rates
Yr 632.6%Yr 729.4%Yr 826.3%Yr 923.1%Yr 1020.0%
35.7% → 20.0%
Years 11–20: glide to long-run rate
Per-year rates
Yr 1118.3%Yr 1216.6%Yr 1314.9%Yr 1413.2%Yr 1511.5%Yr 169.8%Yr 178.1%Yr 186.4%Yr 194.7%Yr 203.0%
20.0% → 3.0%
Beyond year 20: terminal growthPerpetual long-run rate3.0%
Discount rate (cost of equity) 8.1%
Volatility vs market (adjusted beta)0.69

Valuation Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions Sandbox Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Compare with peers

Search any company to compare valuation, profitability, returns, growth, and financial strength side by side.

Compare the target company plus 1 peer. Sign in / Sign up to compare a maximum of 3 peers.

Best in rowHigher is betterLower is better—Data not available
TargetKrystal Biotech IncKRYSHealth Care
Valuation
P/E40.8×
P/S22.8×
P/B7.7×
EV / Revenue21.8×
EV / EBITDA43.2×
Profitability
Gross margin94.6%
Operating margin46.2%
Net margin54.8%
FCF margin58.5%
Returns
ROE17.8%
ROA16.1%
ROIC25.9%
Growth
Revenue growth (YoY)51.6%
5-yr fwd EPS growth29.9%
Financial strength
Debt / Equity0.00×
Current ratio8.32×
Altman Z-Score45.6
Interest coverage—
Dividend yield—

Best value in each row is highlighted. Figures are periodic snapshots from the same filings used across each dossier; a dash means the figure is not available.

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.